Related Experiment Video
Updated: Aug 19, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction
J Chen1, M Godschalk, P G Katz
1Division of Urology, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia.
Abstract:
The recommended dose of prostaglandin E1 as treatment for erectile dysfunction has been reported to be 10 to 40 micrograms. However, adverse effects probably increase with increasing doses. We conducted a prospective, single-blind, dose-escalating study of prostaglandin E1 on 20 men with erectile dysfunction of various etiologies. The response to prostaglandin E1 was assessed by penile palpation and RigiScan rigidity monitoring. A total of 17 patients completed the study: 1 achieved rigidity with 1 microgram., 2 with 2 micrograms. and 4 with 3 micrograms. prostaglandin E1, while more than 70% achieved rigidity with 5 micrograms. or less and more than 80% had a full erection with 20 micrograms. Of 138 injections there were 2 episodes of pain after injection. We conclude that the often recommended starting dose of 20 micrograms. is too high. A more appropriate starting dose is 2.5 micrograms. with increments of 2.5 micrograms. until the lowest effective dose is achieved. This approach may lessen the major impediments to prostaglandin E1 use, that is burning and pain.
More Related Videos
07:36Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
04:22Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Related Concept Videos
Dose-Response Relationship: Potency and Efficacy
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment